The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 93-100

  Qin, Bo ^a,b,c   Budeus, Bettina ^d   Cao, Liang ^a   Wu, Chunchen ^a,b   Wang, Yun ^a   Zhang, Xiaoyong ^b   Rayner, Simon ^a   Hoffmann, Daniel ^d   Lu, Mengji ^a,b   Chen, Xinwen ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Shaoxing Center for Disease Control and Prevention   (China)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Drug resistance; Hepatitis B virus; Hydrodynamic injection mouse model; Nucleoside nucleotide analogs; Replication competence; Tenofovir

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEPATITIS B; HYDRODYNAMICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS REPLICATION;

ADENINE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; ORGANOPHOSPHONATES; RNA-DIRECTED DNA POLYMERASE;

HEPATITIS B VIRUS;

EID: 84871884647     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.007     Document Type: Article

References (32)

1. Amini-Bavil-Olyaee S., Herbers U., Sheldon J., Luedde T., Trautwein C., Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009, 49:1158-1165.
2. Bartholomeusz A., Tehan B.G., Chalmers D.K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. 2004, 9:149-160.
3. Beck J., Nassal M. Hepatitis B virus replication. World J. Gastroenterol. 2007, 13:48-64.
4. Bramucci E., Paiardini A., Bossa F., Pascarella S. PyMod: sequence similarity searches, multiple sequence-structure alignments, and homology modeling within PyMOL. BMC Bioinformatics 2012, 13(Suppl. 4):S2.
5. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouee-Durantel S., Villeneuve J.P., Trepo C., Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41:1391-1398.
6. Delaney W.E., Ray A.S., Yang H., Qi X., Xiong S., Zhu Y., Miller M.D. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 2006, 50:2471-2477.
7. Delaugerre C., Flandre P., Marcelin A.G., Descamps D., Tamalet C., Cottalorda J., Schneider V., Yerly S., LeGoff J., Morand-Joubert L., Chaix M.L., Costagliola D., Calvez V. National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. J. Med. Virol. 2008, 80:762-765.
8. Edgar R.C. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 2004, 5:113.
9. Eswar N., Eramian D., Webb B., Shen M.Y., Sali A. Protein structure modeling with MODELLER. Methods Mol. Biol. 2008, 426:145-159.
10. Gaillard R.K., Barnard J., Lopez V., Hodges P., Bourne E., Johnson L., Allen M.I., Condreay P., Miller W.H., Condreay L.D. Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob. Agents Chemother. 2002, 46:1005-1013.
11. Gan R.B., Chu M.J., Shen L.P., Qian S.W., Li Z.P. The complete nucleotide sequence of the cloned DNA of hepatitis B virus subtype adr in pADR-1. Sci. Sin. B 1987, 30:507-521.
12. Giladi H., Ketzinel-Gilad M., Rivkin L., Felig Y., Nussbaum O., Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther. 2003, 8:769-776.
13. Grant B.J., McCammon J.A., Caves L.S., Cross R.A. Multivariate analysis of conserved sequence-structure relationships in kinesins: coupling of the active site and a tubulin-binding sub-domain. J. Mol. Biol. 2007, 368:1231-1248.
14. Huang L.R., Wu H.L., Chen P.J., Chen D.S. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Nat. Acad. Sci. U.S.A. 2006, 103:17862-17867.
15. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997, 337:1733-1745.
16. Lei Y.C., Hao Y.H., Zhang Z.M., Tian Y.J., Wang B.J., Yang Y., Zhao X.P., Lu M.J., Gong F.L., Yang D.L. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J. Gastroenterol. 2006, 12:4492-4497.
17. Liu Y., Wang C.M., Cheng J., Liang Z.L., Zhong Y.W., Ren X.Q., Xu Z.H., Zoulim F., Xu D.P. Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. Chin. Med. J. (Engl.) 2009, 122:1585-1586.
18. Meng Z., Xu Y., Wu J., Tian Y., Kemper T., Bleekmann B., Roggendorf M., Yang D., Lu M. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. J. Virol. Methods 2008, 150:27-33.
19. Miller M.D., Margot N., Lu B., Zhong L., Chen S.S., Cheng A., Wulfsohn M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 2004, 189:837-846.
20. Pallier C., Castera L., Soulier A., Hezode C., Nordmann P., Dhumeaux D., Pawlotsky J.M. Dynamics of hepatitis B virus resistance to lamivudine. J. Virol. 2006, 80:643-653.
21. Qi X., Xiong S., Yang H., Miller M., Delaney W.E. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther. 2007, 12:355-362.
22. Qiu J., Qin B., Rayner S., Wu C.C., Pei R.J., Xu S., Wang Y., Chen X.W. Novel evidence suggests Hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virol. Sin. 2011, 26:131-138.
23. Sheldon J., Camino N., Rodes B., Bartholomeusz A., Kuiper M., Tacke F., Nunez M., Mauss S., Lutz T., Klausen G., Locarnini S., Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther. 2005, 10:727-734.
24. Soler-Palacin P., Melendo S., Noguera-Julian A., Fortuny C., Navarro M.L., Mellado M.J., Garcia L., Uriona S., Martin-Nalda A., Figueras C. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 2011, 25:171-176.
25. Taly J.F., Magis C., Bussotti G., Chang J.M., Di Tommaso P., Erb I., Espinosa-Carrasco J., Kemena C., Notredame C. Using the T-Coffee package to build multiple sequence alignments of protein, RNA, DNA sequences and 3D structures. Nat. Protoc. 2011, 6:1669-1682.
26. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J. Clin. Virol. 2002, 25:97-106.
27. Tuske S., Sarafianos S.G., Clark A.D., Ding J., Naeger L.K., White K.L., Miller M.D., Gibbs C.S., Boyer P.L., Clark P., Wang G., Gaffney B.L., Jones R.A., Jerina D.M., Hughes S.H., Arnold E. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 2004, 11:469-474.
28. Villet S., Billioud G., Pichoud C., Lucifora J., Hantz O., Sureau C., Deny P., Zoulim F. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009, 136(168-176):e162.
29. Whitcomb J.M., Parkin N.T., Chappey C., Hellmann N.S., Petropoulos C.J. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J. Infect. Dis. 2003, 188:992-1000.
30. Yin Y., Wu C., Song J., Wang J., Zhang E., Liu H., Yang D., Chen X., Lu M., Xu Y. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PLoS One 2011, 6:e22524.
31. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res. 2004, 64:1-15.
32. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137(1593-1608):e1591-1592.